- About BME
- Academics Home
- Combined Degrees
- Student Resources
- Industry Home
- Partner Benefits
- Student Design Projects
- Guest Lectures
- BME Interns
- Research Collaborations
- Tech Licensing
- Industry News
- "Women's Radio Network Open Forum" To Feature AxoGen, Inc.
- 3rd Annual Pruitt Research Day
- AxoGen, Inc. Announces Clearance from FDA to Proceed with New Multicenter Comparative Study for Avance® Nerve Graft
- AxoGen, Inc. Announces Completion of a Pilot Clinical Study Assessing Cavernous Nerve Reconstruction with Avance® Nerve Graft
- BioD LLC Makes $1 Million Gift Commitment to UF BME
- BioD Receives U.S. Patent for Unique Placental Tissue Technology
- Dr. Peter McFetridge awarded the Tim Brahm Professorship
- Event Celebrates BioD’s $1 Million Gift to BME
- New Industry Partner: Sigma Aldrich Corporation
- RTI Surgical™ Announces Agreement With Novation
- SPECIAL EVENT: “Geraldo Rivera Show” to Feature AxoGen, Inc.
- Stryker Provides Guest Lecture to BME Students
- Contact Us
Benjamin G. Keselowsky, Ph.D.
Benjamin G. Keselowsky, Ph.D.
Biomaterials and controlled release systems for vaccines, immunotherapies, and implants
1275 Center Drive, Biomedical Sciences Building J291, Gainesville, FL 32611
B.S., Chemical Engineering, University of South Florida, 1998
Ph.D., Bioengineering, Georgia Institute of Technology, 2004
Dr. Keselowsky’s research has a major focus on the development of innovative vaccines for type 1 diabetes, by formulating biodegradable microparticles and gels to deliver immune modulating factors to key cells in the body. This work is helping to advance immunotherapy treatments for those suffering from this debilitating autoimmune disease.
Dr. Keselowsky has established an internationally-recognized research program in the field of biomaterials, with emphasis on the immunological impact of biomaterials. His research program is multi-disciplinary, working with clinicians, medical scientists, and other engineers. Dr. Keselowsky has been awarded funding from sources such as NIH, NSF, the Arthritis Foundation, and the Juvenile Diabetes Research Foundation.
Dr. Keselowsky co-founded OneVax, LLC, a startup company that is currently located at the Innovation Hub. He founded the company with Todd Brusko, Ph.D. and Clive Wasserfall, M.S., both immunologists within the Department of Pathology, Immunology and Laboratory Medicine, as well as Mark Atkinson, Ph.D., co-director for the UF Health Diabetes Center of Excellence. Working toward commercializing technology developed by the founders, the company’s goal is to keep the immune system from attacking the insulin-producing cells. They are using biomaterials to train the immune system to not be self-destructive and, thus, help to restore glucose imbalances in patients with type 1 diabetes. OneVax was a finalist this past spring for the fifth annual Cade Museum Prize and has successfully obtained two NIH SBIR grants to date.